A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis - Trial NCT06327295
Access comprehensive clinical trial information for NCT06327295 through Pure Global AI's free database. This Phase 2 trial is sponsored by AmtixBio Co., Ltd. and is currently Not yet recruiting. The study focuses on Onychomycosis. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AmtixBio Co., Ltd.
Timeline & Enrollment
Phase 2
Mar 30, 2024
Jan 30, 2026
Primary Outcome
To evaluate the complete cure rate with topical ATB1651 3% and ATB1651 5% in participants with mild to moderate onychomycosis.
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in
 participants with mild to moderate onychomycosis
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06327295
Non-Device Trial